Halozyme Therapeutics (HALO) news
Recent news
Halozyme appoints Danielle Appelhans to its board of directors
AInvest Wire · Aug 18, 2026Halozyme Therapeutics, Inc.: H.C. Wainwright raises target price to $115 from $95
H.C. Wainwright has raised its price target for Halozyme Therapeutics (NASDAQ:HALO) to $115 from $95, maintaining a Buy rating on the stock. This adjustment reflects the firm’s updated financial model, which now includes the anticipated impact of RYBREVANT SC and other strategic developments. The…
AInvest Wire · Aug 7, 2026Halozyme Therapeutics Q2 revenue USD 480.999 million vs. IBES estimate USD 407.5 million
AInvest Wire · Aug 6, 2026Halozyme Therapeutics outlook FY revenue USD 1,835-1,910 million
AInvest Wire · Aug 6, 2026Halozyme sees FY adj EPS $8.65 to $9.00, saw $7.75 to $8.25
Halozyme Therapeutics (NASDAQ: HALO) has raised its fiscal year 2026 adjusted earnings per share (Adj EPS) guidance to a range of $8.65 to $9.00, up from the previous range of $7.75 to $8.25. The updated guidance, issued on August 6, 2026, reflects management’s confidence in the company’s…
AInvest Wire · Aug 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.